In the context of emerging variants of concern, and evidence that patients treated with anti-TNF are at higher risk of breakthrough infection, our data also support the prioritisation of future booster dosing to those with diminished responses to vaccination, including patients taking anti-TNF or tofacitinib. The gene discussed is TNF; the disease is infection.